Actively Recruiting
Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders
Led by Dr. Albert Kar-Kin Chung · Updated on 2025-07-08
40
Participants Needed
1
Research Sites
182 weeks
Total Duration
On this page
Sponsors
D
Dr. Albert Kar-Kin Chung
Lead Sponsor
O
Otsuka Pharmaceutical Co., Ltd.
Collaborating Sponsor
AI-Summary
What this Trial Is About
Not only being the mainstay of treatment for schizophrenia spectrum psychotic disorders, antipsychotics, especially the second-generation antipsychotics (SGAs) have also been recommended as augmenting agents for treating depression. Dopaminergic agents, including both dopamine D2/D3 antagonists and dopamine partial D2 agonists, have been effective for treating psychosis and schizophrenia. Amongst all SGAs, those with partial D2 agonistic property are generally acknowledged to have better side-effect profiles with lower incidence of extrapyramidal side-effects, prolactin increase, weight gain, QTc prolongation, and metabolic syndrome, as well as more efficacious in alleviating depressive symptoms. Up-to-date, three SGAs, namely aripiprazole, brexpiprazole and cariprazine, are known to possess such partial D2 agonism. ReSD-HK study is part of the ReSD Asian Study aiming to carefully evaluate a cohort of patients prescribed with brexpiprazole on its efficacy and tolerability as treatment for schizophrenia and/or depression in a real-life clinical setting.
CONDITIONS
Official Title
Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 65 years at enrollment
- Able to read and communicate in English and/or Chinese
- Able to give informed consent
- Diagnosed with psychotic disorders or major depressive disorder according to DSM-5 or ICD-10
- Receiving brexpiprazole treatment for less than 4 weeks at recruitment
You will not qualify if you...
- Under 18 years old
- Unable to read English or Chinese
- Unable to give informed consent
- Diagnosed with intellectual disabilities or mental retardation according to DSM-5 or ICD-10
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Queen Mary Hospital
Hong Kong, Hong Kong, 000000
Actively Recruiting
Research Team
A
Albert KK Chung, MBBS
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here